Concepts (157)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptor, ErbB-2 | 22 | 2023 | 2651 | 2.750 |
Why?
|
| Trastuzumab | 18 | 2023 | 743 | 2.170 |
Why?
|
| Breast Neoplasms | 34 | 2024 | 16215 | 1.690 |
Why?
|
| Capecitabine | 4 | 2023 | 390 | 1.280 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 21 | 2024 | 16689 | 1.000 |
Why?
|
| Triple Negative Breast Neoplasms | 11 | 2024 | 1386 | 0.810 |
Why?
|
| Oxazoles | 2 | 2020 | 61 | 0.720 |
Why?
|
| Immunoconjugates | 5 | 2023 | 314 | 0.720 |
Why?
|
| Neoadjuvant Therapy | 9 | 2024 | 5231 | 0.720 |
Why?
|
| Antibodies, Monoclonal, Humanized | 6 | 2020 | 3409 | 0.670 |
Why?
|
| Maytansine | 1 | 2016 | 40 | 0.540 |
Why?
|
| Quinazolines | 2 | 2020 | 956 | 0.510 |
Why?
|
| Brain Neoplasms | 6 | 2023 | 4958 | 0.480 |
Why?
|
| Pyridines | 3 | 2020 | 1313 | 0.460 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2014 | 235 | 0.420 |
Why?
|
| Camptothecin | 5 | 2023 | 540 | 0.400 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2019 | 1838 | 0.400 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2014 | 263 | 0.400 |
Why?
|
| Congenital Abnormalities | 1 | 2014 | 280 | 0.390 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2009 | 81 | 0.330 |
Why?
|
| Bone Remodeling | 1 | 2009 | 100 | 0.330 |
Why?
|
| RANK Ligand | 1 | 2009 | 115 | 0.330 |
Why?
|
| Neoplasm Metastasis | 8 | 2020 | 5315 | 0.310 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2021 | 425 | 0.310 |
Why?
|
| Antineoplastic Agents | 4 | 2019 | 14617 | 0.300 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2019 | 4961 | 0.290 |
Why?
|
| Middle Aged | 27 | 2024 | 90352 | 0.290 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2019 | 6256 | 0.280 |
Why?
|
| Adult | 25 | 2024 | 82040 | 0.280 |
Why?
|
| Peptide Fragments | 3 | 2021 | 1309 | 0.260 |
Why?
|
| Female | 36 | 2024 | 148940 | 0.250 |
Why?
|
| Aged | 20 | 2024 | 73333 | 0.250 |
Why?
|
| Biomarkers, Tumor | 4 | 2019 | 10708 | 0.240 |
Why?
|
| BRCA2 Protein | 2 | 2023 | 380 | 0.230 |
Why?
|
| Doxorubicin | 4 | 2024 | 3145 | 0.220 |
Why?
|
| Polysomnography | 1 | 2024 | 175 | 0.220 |
Why?
|
| Humans | 41 | 2024 | 270740 | 0.210 |
Why?
|
| BRCA1 Protein | 2 | 2023 | 528 | 0.210 |
Why?
|
| Antineoplastic Agents, Immunological | 4 | 2020 | 1335 | 0.210 |
Why?
|
| Neoplasm Staging | 4 | 2019 | 14012 | 0.200 |
Why?
|
| Paclitaxel | 3 | 2024 | 2101 | 0.200 |
Why?
|
| Carboplatin | 1 | 2024 | 880 | 0.190 |
Why?
|
| Phthalazines | 2 | 2021 | 262 | 0.190 |
Why?
|
| Sleep Wake Disorders | 1 | 2024 | 372 | 0.180 |
Why?
|
| Maximum Tolerated Dose | 3 | 2019 | 1322 | 0.180 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2024 | 260 | 0.180 |
Why?
|
| Treatment Outcome | 8 | 2023 | 33737 | 0.170 |
Why?
|
| Prognosis | 9 | 2022 | 22505 | 0.160 |
Why?
|
| Consolidation Chemotherapy | 1 | 2019 | 153 | 0.160 |
Why?
|
| Disease-Free Survival | 5 | 2020 | 10265 | 0.160 |
Why?
|
| Breast Neoplasms, Male | 2 | 2019 | 232 | 0.160 |
Why?
|
| Retrospective Studies | 9 | 2024 | 39890 | 0.160 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2024 | 861 | 0.160 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2018 | 153 | 0.150 |
Why?
|
| Molecular Targeted Therapy | 2 | 2018 | 2399 | 0.150 |
Why?
|
| Multiple Myeloma | 1 | 2009 | 2328 | 0.150 |
Why?
|
| ErbB Receptors | 2 | 2024 | 2375 | 0.150 |
Why?
|
| Administration, Oral | 2 | 2019 | 1608 | 0.150 |
Why?
|
| Double-Blind Method | 2 | 2020 | 2580 | 0.140 |
Why?
|
| Bone Neoplasms | 1 | 2009 | 2665 | 0.140 |
Why?
|
| Quinolones | 1 | 2018 | 163 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2018 | 484 | 0.130 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2016 | 164 | 0.130 |
Why?
|
| Diarrhea | 1 | 2019 | 716 | 0.130 |
Why?
|
| Survivors | 2 | 2018 | 1021 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2019 | 5056 | 0.130 |
Why?
|
| Retreatment | 1 | 2016 | 448 | 0.130 |
Why?
|
| Aged, 80 and over | 4 | 2019 | 30998 | 0.120 |
Why?
|
| Clubfoot | 1 | 2014 | 25 | 0.120 |
Why?
|
| Cancer Vaccines | 1 | 2021 | 754 | 0.120 |
Why?
|
| Immunologic Factors | 1 | 2019 | 672 | 0.120 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2018 | 1563 | 0.120 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2024 | 5408 | 0.120 |
Why?
|
| Vesico-Ureteral Reflux | 1 | 2014 | 88 | 0.120 |
Why?
|
| Imatinib Mesylate | 1 | 2018 | 1691 | 0.120 |
Why?
|
| Survival Analysis | 3 | 2023 | 9292 | 0.120 |
Why?
|
| Bevacizumab | 1 | 2017 | 967 | 0.110 |
Why?
|
| Proportional Hazards Models | 3 | 2021 | 5101 | 0.110 |
Why?
|
| Cyclophosphamide | 2 | 2024 | 3245 | 0.100 |
Why?
|
| Deoxycytidine | 1 | 2018 | 1389 | 0.100 |
Why?
|
| Drug Administration Schedule | 1 | 2018 | 3530 | 0.100 |
Why?
|
| RNA, Catalytic | 1 | 2012 | 39 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2022 | 10400 | 0.100 |
Why?
|
| Down Syndrome | 1 | 2014 | 227 | 0.100 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2018 | 1347 | 0.100 |
Why?
|
| Young Adult | 3 | 2020 | 22251 | 0.100 |
Why?
|
| Salvage Therapy | 1 | 2019 | 2123 | 0.090 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2019 | 4000 | 0.090 |
Why?
|
| Fluorouracil | 1 | 2014 | 1990 | 0.090 |
Why?
|
| Osteoprotegerin | 1 | 2009 | 24 | 0.090 |
Why?
|
| Genetic Testing | 1 | 2018 | 1696 | 0.080 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 15218 | 0.080 |
Why?
|
| Neoplasm Grading | 1 | 2014 | 1823 | 0.080 |
Why?
|
| Disease Progression | 2 | 2020 | 6867 | 0.080 |
Why?
|
| Odds Ratio | 1 | 2014 | 2311 | 0.080 |
Why?
|
| Prospective Studies | 2 | 2023 | 13414 | 0.070 |
Why?
|
| Immunotherapy | 1 | 2021 | 3557 | 0.070 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2023 | 520 | 0.070 |
Why?
|
| Germ-Line Mutation | 2 | 2023 | 1101 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2021 | 9042 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2024 | 2828 | 0.060 |
Why?
|
| Ovarian Neoplasms | 1 | 2021 | 4795 | 0.060 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 4960 | 0.060 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2012 | 1269 | 0.060 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2024 | 140 | 0.050 |
Why?
|
| Precision Medicine | 2 | 2021 | 1207 | 0.050 |
Why?
|
| Survival Rate | 3 | 2020 | 12541 | 0.050 |
Why?
|
| Germ Cells | 1 | 2023 | 329 | 0.050 |
Why?
|
| Pregnancy | 1 | 2014 | 8130 | 0.050 |
Why?
|
| Infant, Newborn | 1 | 2014 | 8699 | 0.050 |
Why?
|
| Axilla | 1 | 2024 | 939 | 0.050 |
Why?
|
| HLA-A24 Antigen | 1 | 2021 | 12 | 0.050 |
Why?
|
| Placebo Effect | 1 | 2021 | 37 | 0.050 |
Why?
|
| Anthracyclines | 1 | 2023 | 339 | 0.050 |
Why?
|
| Intention to Treat Analysis | 1 | 2021 | 122 | 0.050 |
Why?
|
| Metaplasia | 1 | 2022 | 384 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2019 | 2069 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2023 | 9470 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2020 | 413 | 0.040 |
Why?
|
| Mastectomy | 1 | 2024 | 1553 | 0.040 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2019 | 153 | 0.040 |
Why?
|
| Pyrroles | 1 | 2021 | 588 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2019 | 927 | 0.040 |
Why?
|
| Receptors, Steroid | 1 | 2019 | 337 | 0.040 |
Why?
|
| Logistic Models | 1 | 2024 | 3444 | 0.040 |
Why?
|
| Elafin | 1 | 2017 | 35 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2019 | 544 | 0.030 |
Why?
|
| Risk | 1 | 2021 | 1939 | 0.030 |
Why?
|
| Lymph Node Excision | 1 | 2024 | 2062 | 0.030 |
Why?
|
| Gene Amplification | 1 | 2018 | 766 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2019 | 1356 | 0.030 |
Why?
|
| Ventricular Function, Left | 1 | 2019 | 564 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2021 | 1754 | 0.030 |
Why?
|
| Contrast Media | 1 | 2022 | 1499 | 0.030 |
Why?
|
| Age Factors | 1 | 2024 | 5457 | 0.030 |
Why?
|
| Everolimus | 1 | 2017 | 436 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2019 | 513 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2020 | 2313 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2024 | 3077 | 0.030 |
Why?
|
| Benzamides | 1 | 2019 | 1879 | 0.030 |
Why?
|
| Child | 1 | 2014 | 30559 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2024 | 12103 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2017 | 654 | 0.030 |
Why?
|
| Sirolimus | 1 | 2017 | 831 | 0.030 |
Why?
|
| Piperazines | 1 | 2021 | 2145 | 0.030 |
Why?
|
| Neoplasms | 1 | 2018 | 15927 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 625 | 0.020 |
Why?
|
| Male | 3 | 2019 | 128315 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 121 | 0.020 |
Why?
|
| Mutation | 2 | 2023 | 15912 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2021 | 3669 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2020 | 7655 | 0.020 |
Why?
|
| Mice | 1 | 2009 | 35600 | 0.020 |
Why?
|
| Risk Factors | 1 | 2024 | 17888 | 0.020 |
Why?
|
| Stomach Neoplasms | 1 | 2018 | 2331 | 0.020 |
Why?
|
| Animals | 1 | 2009 | 61956 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 5776 | 0.010 |
Why?
|